NCT Number: NCT02519374
Fiber Tolerability in Children
Assessment of the digestive tolerability of the PROMITOR® .
Looking for future studies?
Notify MeKey information
Conditions
Age range
8 year–12 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Biofortis, Saint-Herblain, France
About this study
The trial will be multicenter, double-blind, placebo-controlled, randomized with a 4-arm parallel-design. The subjects wil be randomized to one of the four arms, i.e. four doses of investigational product balanced in maltodextrin, given at the doses of 6, 9 or 12 g (corresponding to 4, 6, or 8 g of fibers) twice a day with the meals of the morning and of the evening versus control (maltodextrin, no fibers) over one week of intake.
The total sample size is 40 healthy children from 8 to 12 years old, male and female.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy children,
- Aged between 8 and 12 years old included
- Acceptance of the taste of the product
- Having breakfast on daily basis
- Consent and/or assent received according to regulation
- Informed consent of one of the parents/guardians (for the study to be conducted in Switzerland, in respect with the Swiss regulation) or Informed consent of both parents/guardians (for the study to be conducted in France, in respect with the French regulation)
- Parents/guardians affiliated to a health insurance (only for the study to be conducted in France, in respect with the French regulation)
Exclusion criteria
- Specific food regimen
- Intolerability or food allergy
- Antibiotic or any medication impacting the gut transit during the 2 weeks before the study
- Chronic gastrointestinal disease
- Gastroenteritis in the 2 weeks preceding the study
- Constipation or diarrhea based on ROMEIII criteria (in average: more than 3 stools per day or less than 3 stools per week)
- Children and parents expected not to understand and perform the trial correctly (i.e.: troubles in learning and/or speaking)
- Child in a situation which, in the opinion of the principal investigator, could interfere with the optimal participation to the study or constitute a particular risk of non-compliance
- Having participated in another clinical trial for 1 month, or currently participating in a clinical trial
- Under legal protection or deprived from his rights following administrative or judicial decision (only for the study to be conducted in France, in respect with the French regulation)
Treatment and study plan
PROMITOR® (including Maltodextrin)
DrugInvestigational product dose 1
Primary outcomes
-
Assessment of the digestive tolerability of the Investigational Product (abdominal pain)
Time frame: 7 days of intake
Using analog visual scale
-
Assessment of the digestive tolerability of the Investigational Product (rumbling)
Time frame: 7 days of intake
Using analog visual scale
-
Assessment of the digestive tolerability of the Investigational Product (bloating)
Time frame: 7 days of intake
Using analog visual scale
-
Assessment of the digestive tolerability of the Investigational Product (flatulence)
Time frame: 7 days of intake
Using analog visual scale
-
Assessment of the digestive tolerability of the Investigational Product (stools consistency & frequency)
Time frame: 7 days of intake
Using analog visual scale
Sponsors and collaborators
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Registry information
Acronym: FITIC
Important dates
- Study start
- 2015
- Primary completion
- 2015
- Study completion
- 2015
- First posted
- Aug 10, 2015
- Registry last updated
- Feb 5, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Efficacy of Guided Imagery Therapy Mobile Application for Functional Abdominal Pain
NCT06653647
Abdominal Pain, Abdominal Pain/ Discomfort
Houston, Texas, United States
View Trial DetailsEfficacy And Safety Of Probiatop In The Treatment Of Digestive Symptoms
NCT05603403
Pathological Conditions, Signs and Symptoms, Signs and Symptoms
Valinhos, São Paulo, Brazil
View Trial DetailsEvaluation of the Composition of Human Milk and Health Outcomes in Children
NCT01431482
Anemia, Hematologic Diseases
View Trial DetailsFiber Tolerability in Children Aged 3-7 Year
NCT02677090
Pathological Conditions, Signs and Symptoms, Signs and Symptoms
Saint-Herblain, France
View Trial Details